/PRNewswire/ Dr. Guru Sonpavde is the Bladder Cancer Director at the Dana-Farber Cancer Institute, an Associate Professor of Medicine at Harvard Medical.
Vial adds Dr Guru Sonpavde of the Dana-Farber Cancer Institute to their Oncology CRO Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Dr. Guru Sonpavde is the Bladder Cancer Director at the Dana-Farber Cancer Institute, an Associate Professor of Medicine at Harvard Medical.
GSRGT 2020: The Need for Perioperative Management Strategies: Role of Clinical Oncologists - Chemotherapy
(UroToday.com) The penile cancer session at the Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit included a discussion for the role of chemotherapy in the perioperative management of patients with penile cancer by Dr. Guru Sonpavde from the Dana-Farber Cancer Institute. Dr. Sonpavde notes that surgery alone for patients with locally advanced disease is associated with high-risk of recurrence, both locoregionally and distant, with 5-year overall survival (OS) rates of 0-42%. Particularly bad predictors include bulky inguinal adenopathy of ≥ 4cm, bilateral nodes, pelvic lymphadenopathy (N3 disease), an unresectable primary tumor (T4), and extranodal extension.